11.06.2007 12:00:00
|
King Pharmaceuticals Joins Together Rx Access(TM) To Help Americans Without Prescription Drug Coverage
King Pharmaceuticals, Inc. (NYSE:KG) announced today that it is the 11th
pharmaceutical company to join Together Rx Access,™
a prescription savings program created by leading pharmaceutical
companies to help individuals and families gain access to meaningful
savings on prescription medicines.
"We are extremely pleased to welcome King
Pharmaceuticals as a new member company and commend its commitment to
helping Americans without prescription drug coverage gain access and
savings,” said Roba Whiteley, executive
director of Together Rx Access. "The Together
Rx Access™ Program continues to gain momentum,
enrolling nearly 10,000 Americans each week.”
An estimated 47 million Americans, including nine million children, do
not have healthcare coverage. The uninsured population includes
two-income families, single parents, the self-employed, recent college
graduates, and low-wage workers, among others. In fact, eight out of 10
uninsured people are in families where one or more members are employed.
"We are proud to participate in the Together
Rx Access Program, which offers immediate help to eligible individuals
and their families, and has proven it can make a real difference,”
said Brian A. Markison, Chairman and CEO of King Pharmaceuticals, Inc. "This
program is a great example of our industry recognizing and responding to
a public need by coming together to develop and participate in an
innovative and effective solution.” "The participation of King Pharmaceuticals
enhances the Together Rx Access Program’s
value to cardholders by expanding the number of brand-name prescription
medicines in the Program, including those to treat many common
conditions such as hypertension, hypothyroidism and chronic pain,”
added Whiteley.
King’s participation in the Together Rx
Access Program will provide cardholders with savings on products such as
Altace® (ramipril);
Skelaxin®
(metaxalone); Avinza® (morphine
sulfate extended release); Sonata®
(zaleplon); and Levoxyl®
(levothyroxine sodium tablets, USP).
King Pharmaceuticals joins the following companies already participating
in the Together Rx Access Program: Abbott Laboratories; AstraZeneca
Pharmaceuticals LP; Bristol-Myers Squibb Company; GlaxoSmithKline;
Janssen, L.P.; Johnson & Johnson Wound Management, a Division of
ETHICON, Inc.; LifeScan, Inc.; McNeil Pediatrics, a Division of
McNeil-PPC, Inc.; Novartis Pharmaceuticals Corporation; Ortho Biotech
Products, L.P.; Ortho-McNeil, Inc.; Ortho-McNeil Neurologics, Inc.;
OrthoNeutrogena, a Division of Ortho-McNeil Pharmaceutical, Inc.; Ortho
Women’s Health & Urology, a Division of
Ortho-McNeil Pharmaceutical, Inc.; Pfizer Inc; PriCara, a Unit of
Ortho-McNeil, Inc.; sanofi-aventis U.S. LLC.; Takeda Pharmaceuticals
North America, Inc.; TAP Pharmaceutical Products Inc.; Tibotec
Therapeutics, a Division of Ortho Biotech Products, L.P.; and Vistakon
Pharmaceuticals, LLC.
About King Pharmaceuticals, Inc.
King Pharmaceuticals, headquartered in Bristol, Tennessee, is a
vertically integrated branded pharmaceutical company. King, an S&P 500
Index company, seeks to capitalize on opportunities in the
pharmaceutical industry through the development, including through
in-licensing arrangements and acquisitions, of novel branded
prescription pharmaceutical products in attractive markets and the
strategic acquisition of branded products that can benefit from focused
promotion and marketing and product life-cycle management.
About Together Rx Access
The Together Rx Access Card was created by leading pharmaceutical
companies to help hardworking Americans and their families gain access
to meaningful savings on prescriptions right at their neighborhood
pharmacy. Most cardholders save 25 to 40 percent1
on brand-name prescription products, including medicines to treat high
cholesterol, diabetes, asthma, and many other conditions. More than 300
brand-name prescription products2 are included
in the Program. Savings are also available on a range of generic
products.
To qualify for the free Together Rx Access Card, applicants cannot be
eligible for Medicare or have public or private prescription drug
coverage. To be eligible, household income of less than $30,000 for a
single person or $60,000 for a family of four (income eligibility is
adjusted for family size) is required. Applicants must be legal
residents of the United States or Puerto Rico. It is easy to enroll in
the Program and easy to use the Card once enrolled. The Card is accepted
at the majority of pharmacies nationwide and in Puerto Rico. Cardholders
simply bring the Card to their pharmacist along with their prescription,
and the savings are calculated right at the pharmacy counter. There are
no enrollment costs, monthly dues or hidden charges.
Together Rx Access also directs individuals to the Partnership for
Prescription Assistance (PPA), a clearinghouse for more than 475 public
and private assistance programs, including 180 offered by pharmaceutical
companies.
For more information about the Together Rx Access Card and to enroll in
the Program, contact Together Rx Access at 1-800-966-0407, or visit TogetherRxAccess.com.
Together Rx Access and the Together Rx Access logo are trademarks of
Together Rx Access, LLC. All other marks are the property of their
respective owners.
© 2007 Together Rx Access, LLC.
1 Each card user's savings depend on such
factors as the particular drug purchased, amount purchased, and the
pharmacy where purchased. Participating companies independently set the
level of savings offered and the products included in the program. Those
decisions are subject to change.
2 Visit TogetherRxAccess.com
for the most current list of brand-name medicines and products.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Pfizer Inc.mehr Nachrichten
Analysen zu Pfizer Inc.mehr Analysen
14.11.24 | Pfizer Neutral | UBS AG | |
01.11.24 | Pfizer Neutral | UBS AG | |
30.10.24 | Pfizer Buy | Goldman Sachs Group Inc. | |
29.10.24 | Pfizer Buy | Jefferies & Company Inc. | |
24.10.24 | Pfizer Neutral | JP Morgan Chase & Co. |
Aktien in diesem Artikel
Pfizer Inc. | 24,57 | 0,74% |
Indizes in diesem Artikel
S&P 500 | 5 998,74 | -0,38% |